Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
WuXi CEO Seeks To Take Firm Private
by Michael McCoy
May 4, 2015
| A version of this story appeared in
Volume 93, Issue 18
WuXi Pharmatech, a Chinese provider of drug R&D and manufacturing services, has received a takeover offer worth more than $3 billion from founder and CEO Ge Li and Ally Bridge Group Capital Partners. WuXi will form a committee to consider it. Li founded WuXi in 2000, expanding it into a research outsourcing behemoth with more than 8,000 employees and sales last year of $674 million. Last week the firm announced that it is building the world’s largest disposable-bioreactor-based mammalian cell culture facility in the city of Wuxi, China.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter